For all media enquiries please email us on media@melanoma.org.au
Pooled analysis of five-year survival: neoadjuvant immunotherapy for melanoma translates to real-world care
An international pooled study led by Professor Georgina Long AO, and published in Nature Medicine, showed patients whose tumours responded well to neoadjuvant immunotherapy had outstanding 5-year survival.
Prof Georgina Long awarded Eureka Prize for Scientific Research
Read more about the Australian Museum 2026 Eureka Prizes and the transformative scientific research led by Professor Long.
Maria Gonzalez appointed CEO of Melanoma Institute Australia
The Board of MIA has appointed Maria Gonzalez as Chief Executive Officer following a comprehensive external search. Maria has led MIA as Interim CEO since December 2025. Read more about how Maria has been a senior leadership team member at MIA for sixteen years, helping build the organisation.
Location and type of immune cells affects treatment response
Read more about how researchers at Melanoma Institute Australia and The University of Sydney have led the way in showing that it’s not just the number of immune cells in a tumour that influences treatment response - it’s also where those cells are located and their type.
Recordings of MPA-MIA Melanoma Community Webinar Series 2026
Watch recordings of our MPA-MIA Melanoma Community Webinar series. All three recordings are now available: Your melanoma nurse, Endocrine side effects of immunotherapy, and Understanding sentinel lymph node biopsies.
Prof Georgina Long & Dr Kerry Crotty share tribute to Prof Richard Scolyer
As published in The Australian, Prof Richard Scolyer AO’s friends and colleagues, Professor Georgina Long AO and Dr Kerry Crotty, share their reflections on Richard’s extraordinary spirit, his exceptional contributions to the fields of melanoma and pathology, and his lasting legacy.
Prof Georgina Long to build on strong global melanoma research collaboration in Europe
Over the next three months, Prof Georgina Long will work with some of Europe's leading cancer research and treatment centres, advancing collaborative research in melanoma and neoadjuvant immunotherapy.
Vale Professor Richard Scolyer AO
All of us at Melanoma Institute Australia (MIA) and the wider melanoma community are mourning the loss of our esteemed colleague and friend, Professor Richard Scolyer AO.
MIA team share learnings at key international conferences
Read more about how the MIA team continues to play a leading role in advancing the frontiers of melanoma research, presenting new findings at major international oncology conferences - the AACR Annual Meeting in San Diego, the EADO Congress in Prague, and ASCO in Chicago.
Streamlining assessment of pathological response after neoadjuvant treatment
Neoadjuvant immunotherapy continues to transform outcomes for people with melanoma and other cancers. Two recent papers show that assessing pathological response after neoadjuvant immunotherapy can be both more efficient and more consistent, without compromising accuracy.
Melanoma March 2026 in pictures
See all the photos from our Melanoma March 2026 events, and download yours.
UV exposure leading cause of preventable cancers for Australian men
A World Health Organisation global study published in the Nature Medicine journal showed that 2 in every 5 cancers could be prevented. It found that in Australia the leading risk factor for preventable cancers in men is exposure to UV radiation.
Suzanne Sherwood says:
Steve Cole says:
Catherine Mardell says: